Houston, TXNCT05054296Now EnrollingIRB Ready

Biochemically Recurrent Prostate Carcinoma Clinical Trial in Houston, TX

Access cutting-edge biochemically recurrent prostate carcinoma treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access biochemically recurrent prostate carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related biochemically recurrent prostate carcinoma treatment provided free

Apply for This Houston Location

Check if you qualify for this biochemically recurrent prostate carcinoma clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Biochemically Recurrent Prostate Carcinoma Study in Houston

This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with prostate cancer that has spread to other places in the body (metastatic) or has come back (recurrent) and does not response to treatment (refractory) and are receiving androgen deprivation therapy. Balancing treatment efficacy, drug side effects, and competing comorbidities with prostate cancer is essential. This trial is being done to learn if an exercise program can help to improve metabolic syndrome and cardiovascular (heart) fitness in prostate cancer patients who are receiving androgen deprivation therapy.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Willing and able to provide written informed consent
Histologically or cytologically confirmed adenocarcinoma of the prostate
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography \[CT\] and/or magnetic resonance imaging \[MRI\]) or biochemical recurrence/refractoriness following local therapy (prostatectomy or radiation)
Stable or improving disease activity as demonstrated by stable or improving PSA over at least 2 months
On gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist or status post-surgical castration for at least 3 months
Combination ADT with abiraterone or enzalutamide is permitted
Anticipation to remain hypogonadal for at least 6 months subsequently
Asymptomatic bone metastasis is permissible (exercise will be modified and patients monitored)
Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
Patients must be able to finish a maximal exercise stress test which will be assessed by cardiopulmonary exercise testing using a standardized protocol \^70 supervised by a cardiologist
Hemoglobin \>= 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to enrollment
Platelet count \>=75,000/uL independent of transfusion and/or growth factors within 3 months prior to enrollment
Access to a smart phone with android or iPhone OS (iOS) operating systems
Able to speak and comprehend English

Exclusion Criteria

Current use of any other systemic therapy for prostate cancer with the exception of gonadotrophin releasing hormone (GnRH) agonists/antagonists, abiraterone, enzalutamide, bisphosphonates or RANK-ligand inhibitors (for bone metastases) which are allowed
Any underlying comorbid medical or psychiatric condition, which in the opinion of the Investigator, will make participation in our exercise intervention hazardous or obscure the interpretation of adverse events
Inability to walk 400 meters or undertake upper and lower limb exercise, and resistance training in the previous 3 months
Chemotherapy treatment within 28 days of study enrollment
Symptomatic bone metastasis
Any investigational pharmaceutical products
Radiation therapy or surgical intervention for prior bone metastasis
Clinically significant active malignancy other than prostate cancer
Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (\>= 450 m/sec)
Clinically significant heart disease that may impact safety of independent or supervised exercise including preexisting coronary artery disease, myocardial infarction or arterial thrombotic events in the past 6 months, severe or unstable angina, history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsade de pointes), New York Heart Association Class III-IV heart disease or cardiac ejection fraction measurement of \< 40% at baseline
Untreated symptomatic spinal cord compressions
Prisoners or subjects who are involuntarily incarcerated
Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT05054296) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Biochemically Recurrent Prostate Carcinoma Treatment Options in Houston, TX

If you're searching for biochemically recurrent prostate carcinoma treatment options in Houston, TX, this clinical trial (NCT05054296) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced biochemically recurrent prostate carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all biochemically recurrent prostate carcinoma clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Houston, TX

See all prostate cancer clinical trials recruiting in Houston — not just this study.

Browse Prostate Cancer Trials in Houston →

Browse More Trials by Condition

Prostate Cancer TrialsLeukemia TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX